FORM 6-K

 

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

 

dated July 16, 2018

 

Commission File Number 0-51504

 

GENETIC TECHNOLOGIES LIMITED

(Exact Name as Specified in its Charter)

 

N/A

(Translation of Registrant’s Name)

 

60-66 Hanover Street

Fitzroy

Victoria 3065 Australia

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F   x       Form 40-F   o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):   o

 

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes   o                    No   x

 

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):  Not applicable.

 

 

 


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused the Report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: July 16, 2018

 

 

 

 

GENETIC TECHNOLOGIES LIMITED

 

 

 

By:

/s/ Kevin Fischer

 

 

Name:

Kevin Fischer

 

 

Title:

Company Secretary

 

2


 

EXHIBIT INDEX

 

Exhibit

 

Description of Exhibit

 

 

 

99.1

 

ASX Announcement, July 16, 2018

 

3

Exhibit 99.1

 

 

ASX ANNOUNCEMENT

16 July 2018

 

Genetic Technologies Limited announces the expansion of its range of genetic risk assessment tests plus the October launch of its new breast cancer and colorectal cancer tests.

 

Melbourne, Australia, 16 July 2018: Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, announced today that both its new breast cancer and colorectal cancer risk assessment tests are on track for release in October 2018.  In addition the company has already commenced development of other cancer and disease targets for its predictive technologies. The company expects to have the following tests available over the next 12 months:

 

·                   Prostate Cancer

·                   Melanoma

·                   Type 2 Diabetes

·                   Cardiovascular Disease

 

For perspective, there are 17.7 million deaths per annum due to cardiovascular disease, 8.2 million deaths per annum due to cancer and 1.6 million deaths per annum due to diabetes. (Source: World health Organisation).

 

Genetic Technologies Chairman and CEO, Dr Paul Kasian commented: “This is a very exciting time for GTG. We are now offering an opportunity for doctors to improve their ability to assess a patient’s breast cancer risk. Our new test, when combined with BRCA testing, will account for almost 100% of breast cancers. Currently BRCA testing alone only accounts for 5 to 10% of breast cancers.  Added to this our expanded range of tests will allow doctors to assess a patient’s risk to some of the most common causes of morbidity and mortality. ”

 

FOR FURTHER INFORMATION PLEASE CONTACT

 

Dr Paul Kasian

 

Jason Wong (USA))

Director & Interim CEO

 

Blueprint Life Science Group

Genetic Technologies Limited

 

+1 (415) 375 3340, Ext. 4

+ 61 3 8412 7000

 

 

 

Genetic Technologies Limited · Website : www.gtglabs.com · Email : info@gtglabs.com    ABN 17 009 212 328

Registered Office · 60-66 Hanover Street Fitzroy Victoria 3065 Australia · Postal Address P.O. Box 115 Fitzroy Victoria 3065 Australia

Phone +61 3 8412 7000 · Fax +61 3 8412 7040

 


 

About Genetic Technologies Limited

 

Genetic Technologies is a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead product, BREVAGen plus ® , is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class.  For more information, please visit www.brevagenplus.com and www.phenogensciences.com.

 

Genetic Technologies is developing a pipeline of risk assessment products including a novel colorectal cancer (CRC) test. For more information, please visit www.gtgcorporate.com

 

Safe Harbor Statement

 

Any statements in this press release that relate to the Company’s expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company’s actual results may differ materially from expected results. Additional risks associated with Genetic Technologies’ business can be found in its periodic filings with the SEC.